MD PhD / Prof of Internal Medicine / National Referal Center #autoimmune diseases #SNFMI #GFEV #GEFA @CHUDijon @univbourgogne
Dijon, France
Joined July 2022
- Tweets321
- Following200
- Followers235
- Likes271
Maxime Samson retweeted
✉️Edito
Quelle est la place du Sécukinumab dans la prise en charge de l'artérite à cellules géantes ? Interprétation des résultats de l'étude GCAptAIN et proposition d'inclusion des anti-IL17A dans les recommandations :
sciencedirect.com/science/ar…
Maxime Samson retweeted
Presented at #EULAR2026:
Among patients with relapsed polymyalgia rheumatica, treatment with secukinumab plus a 24-week glucocorticoid taper resulted in a higher percentage of patients with remission than a glucocorticoid taper alone. Full phase 3 REPLENISH trial results: nej.md/3PvmmMO
Editorial: Emerging Era for Polymyalgia Rheumatica and GCA — Interleukin-17A Targeting nej.md/4dB5b5I
Original Article in @NEJMEvidence: Secukinumab for Giant Cell Arteritis (phase 3 GCAptAIN trial) eviden.cc/49CLAj9
@eular_org
ALT Chart from an article published in the New England Journal of Medicine showing results from a phase 3 trial of secukinumab in polymyalgia rheumatica. Two bar graphs depict sustained remission and complete sustained remission at week 52, comparing secukinumab, 300 mg (dark blue bars); secukinumab, 150 mg (light blue bars); and placebo (grey bars). Statistical significance is noted with P<0.001 for each comparison.
Maxime Samson retweeted
📢 NEWS ALERT!
#EULAR has released an update to the recommendations for managing Behçet’s syndrome, reflecting advances in evidence and treatment strategies.
Read the full #eularPressRelease here 👉 pulse.ly/8bgmepplgl
#BehcetsSyndrome #Rheumatology
Maxime Samson retweeted
🔔Alerte nouveau PNDS 🔔
Découvrez le PNDS sur le diagnostic et la prise en charge des péricardites récidivantes :
sciencedirect.com/science/ar…
Avec notre éditorial : "Péricardites : un nouveau paradigme ?"
sciencedirect.com/science/ar…
#PNDS #Guidelines #pericarditis #recurrent
Maxime Samson retweeted
Very important data!
Presented at the 15th European Lupus Meeting:
In patients with SLE without advanced lupus nephritis, obinutuzumab plus standard therapy was superior to placebo plus standard therapy in conferring and sustaining a clinically meaningful reduction in disease activity over 52 weeks. Full phase 3 ALLEGORY trial results: nejm.org/doi/full/10.1056/NE…
#SLEuro | @SLEuroSociety
ALT 15th European Lupus Meeting Original Article | MAR 6, 2026 | NEJM.org Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus Figure 1A. Time to First BILAG Flare.
Maxime Samson retweeted
Lancement officiel de Corticomed, l'outil d'aide à la décroissance des corticoides en médecine interne. Gratuit, simple et basé sur les recommandations nationales et internationales. share.google/aVhMWV6wi9Pheni…
Maxime Samson retweeted
💡#GCA epidemiology is fascinating 🤯
Its incidence varies inexplicably with constitutional & environmental factors🌍
➡️Check out our latest SR-MA in @Rheumatol_Int & as we focus on seasonality & latitude influence on #GCA & how both can be connected
🔗 shorturl.at/1kyOL
Maxime Samson retweeted
For anyone interested in #VEXAS check out the 2nd international workshop happening Sept @nyulangone in NYC. @petercgrayson @bhavishap29 @sinisauksav @SophieGeorgin @MikkaelSekeres @thibault_comont @TerrierBen highmarksce.com/nyumc/index.…
Maxime Samson retweeted
🚨🚨🚨 AHHH we have just been granted a 🔓 FREE 50-DAY ACCESS LINK to the expert #consensus on the therapeutic management of RARE systemic #lupus erythematosus manifestations
Can you please re-tweet the link so that a MAXIMUM have access for free 🔄 LINK: authors.elsevier.com/a/1l8og…
Maxime Samson retweeted
Thrilled and honored to speak for this session in Barcelona
As Erdheim-Chester Disease (ECD) becomes more recognized and understood within the medical community, a new challenge is emerging: what happens when a patient’s symptoms don’t follow a predictable pattern, or worse, when ECD isn’t the only condition ...
erdheim-chester.org/keynote-…
Maxime Samson retweeted
Interested in vasculitis? Don’t miss the 6th EUVAS Vasculitis Course! May 21–24, 2025. Trieste, Italy !
Stay up to date with the latest in vasculitis
The course is fully booked for onsite participation. But available online. – register today!
eventi.eve-lab.com/congresso…
Maxime Samson retweeted
Impact of autoantibody status on stratifying the risk of organ involvement and mortality in SSc
⏩1605 patients
⏩ associations between each AAb and internal organ involvement
⏩skin phenotype was not an independent factor
rmdopen.bmj.com/content/10/4…
Maxime Samson retweeted
@SNFMI_Medical
Soyons fiers de nos jeunes internistes @AJInternistes qui ont brillamment présenté leurs travaux 🤩 et représenté notre spécialité 😍 au congrès international de l'ACR 2024 à Washington 🇺🇸 ! Bravo à tous 👏
Merci à @contactfai2r !
Merci à @SNFMI_Medical !
Maxime Samson retweeted
Glucocorticoids versus glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis with poor-prognosis factors!
Click here to read or download the article!📢📢📢
sciencedirect.com/science/ar…
Maxime Samson retweeted
Geoffroy Peyrac on the podium for the Newton study 🚀🚀🚀! Excellent talk by Geo !!! 👏💫 #ACR2024 @thitran3 @AJInternistes @SNFMI_Medical @contactfai2r @HopLariboisiere
Maxime Samson retweeted
Hydroxychloroquine and Cardiovascular Events in Patients With Systemic Lupus Erythematosus jamanetwork.com/journals/jam…
Maxime Samson retweeted
La rentrée approche à grands pas et notre weekend de pré-rentrée pour les nouveaux internes en médecine interne aussi !
Trouvez le programme ci joint !
Inscription ici : form.jotform.com/24256100446…
A très vite !
Maxime Samson retweeted
Dans notre Portrait du mois, découvrez l'interview du Pr Bertrand Godeau
"à chaque nouveau service, je changeais d’avis jusqu’à mon passage dans le service du Pr Annette Schaeffer...
@ce_medinterne @SNFMI_Medical
doi.org/10.1016/j.revmed.202…
Maxime Samson retweeted
Le logement, les activités et repas seront financés pour les 70 premiers inscrits !
Dépêchez vous, il reste encore quelques places !
Lien d’inscription : form.jotform.com/24256100446…
A très vite 🔥